Binah Capital Group Inc
Financial Services
Binah Capital Group Inc (BCG) Stock News
The latest BCG headlines and market coverage — 4 recent stories, updated throughout the day.
- Benzinga·
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
ImmunityBio announced an exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG to treat bladder cancer, backed by positive Phase 3 trial data showing non-inferiority to TICE BCG. The company also secured five U.S. patents for its ANKTIVA plus BCG platform through 2035. Despite the news, IBRX shares fell 1.13% to $7.88 on Monday.
- Benzinga·
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
ImmunityBio Inc. (NASDAQ: IBRX ) on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder cancer treatment in the U.S. ImmunityBio Secures Exclusive Rights To Tokyo-Strain BCG The agreement gives ImmunityBio exclusive U.S. rights to intravesical Tokyo-172 BCG, an investigational therapy that has not yet received Food and Drug Administration (FDA) approval. The company said the partnership follows positive Phase 3 data from the SWOG S1602 trial, sponsored by the National Cancer Institute, which showed the Tokyo strain was non-inferior to TICE BCG in patients with BCG-naïve high-grade non-muscle invasive bladder cancer (NMIBC). ImmunityBio will serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address the over decade long unresolved BCG shortage in the United States data-variant="card" data-news-mode="manual" ... Full story available on Benzinga.com
- GlobeNewswire Inc.·
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology announced positive Phase 2 results from CORE-008 Cohort CX evaluating intravesical cretostimogene combined with gemcitabine in high-risk BCG-exposed and BCG-unresponsive bladder cancer patients. The trial demonstrated high complete response rates (85.7-92.3%), high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months, with a favorable safety profile and no Grade 3+ treatment-related adverse events.
- GlobeNewswire Inc.·
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics reported positive 12-month efficacy and safety data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer patients, demonstrating a 55% complete response rate at 12 months with no Grade 3 or greater adverse events. The company plans to initiate the registrational ADVANCED-3 trial in the second half of 2026 and submit a BLA for TARA-002 in lymphatic malformations in 2H 2027.